Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer
Overall survival was significantly longer with the combination of enzalutamide and leuprolide than with leuprolide alone among patients with prostate cancer with high-risk biochemical recurrence. Enzalutamide monotherapy was not superior to leuprolide alone in the analysis of overall survival. (Funded by Pfizer and Astellas Pharma; EMBARK ClinicalTrials.gov number, NCT02319837.).
Authors
- Murilo Luz (ORCID: https://orcid.org/0000-0002-0575-5635)
- Christopher Pieczonka (ORCID: https://orcid.org/0000-0002-2531-7587)
- Choung‐Soo Kim (ORCID: https://orcid.org/0000-0002-7464-3207)
- Yiyun Tang (ORCID: https://orcid.org/0000-0001-9810-1288)
- Stephen J. Freedland (ORCID: https://orcid.org/0000-0002-8104-6419)
- M. Backhaus (ORCID: https://orcid.org/0000-0001-6214-784X)
- Antti Rannikko (ORCID: https://orcid.org/0000-0002-4261-3484)
- Arnauld Villers (ORCID: https://orcid.org/0000-0002-6298-7758)
- Matko Kalac (ORCID: https://orcid.org/0000-0003-1238-0760)
- Ronald Tutrone (ORCID: https://orcid.org/0000-0001-6705-778X)
- Martin Gleave (ORCID: https://orcid.org/0000-0003-4235-0167)
- Swetha Sridharan (ORCID: https://orcid.org/0000-0001-6337-8543)
- Ugo De Giorgi (ORCID: https://orcid.org/0000-0001-7520-2908)
- Henry Hyunshik Woo (ORCID: https://orcid.org/0000-0003-4099-0339)
- Geoffrey Gotto (ORCID: https://orcid.org/0000-0001-6637-2032)
- Neal D. Shore (ORCID: https://orcid.org/0000-0001-5767-0548)
- Balaji Venugopal
- Gabriel P. Haas
- Matt Rosales
- Fong Wang
Institutions
- Cedars-Sinai Medical Center (US)
- University of Helsinki (FI)
- Ewha Womans University (KR)
- University of British Columbia (CA)
- SAIT Polytechnic (CA)
- University of Calgary (CA)
- Pfizer (United States) (US)
- SUNY Upstate Medical University (US)
- Université de Lille (FR)
- Beatson West of Scotland Cancer Centre (GB)
- Helsinki University Hospital (FI)
- Blacktown & Mount Druitt Hospital (AU)
- Chris O’Brien Lifehouse (AU)
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT)
- Fundación Instituto Valenciano de Oncología (ES)
- Hospital Erasto Gaertner (BR)
- Durham VA Medical Center (US)
- Calvary Mater Newcastle Hospital (AU)
- Chesapeake Urology Associates (US)
- Hôpital Claude Huriez (FR)
- Carolina Urologic Research Center (US)
- Astellas Pharma (United States) (US)
- University of Glasgow (GB)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2025-10-19
- DOI
- https://doi.org/10.1056/nejmoa2510310
- Citations
- 13
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 19.74